Algernon Pharmaceuticals
Algernon Pharmaceuticals is a Canadian clinical stage drug development and repurposing company investigating multiple drugs for unmet global medical needs. The company focuses on innovative drug repurposing models, advancing a proprietary form of DMT for stroke and traumatic brain injury through its subsidiary Algernon NeuroScience, and establishing Alzheimer’s diagnostic and treatment clinics utilizing new PET scan technology. It aims to address significant gaps in the diagnosis and treatment of neurological diseases, leveraging recent FDA approvals and advanced imaging technology to create a comprehensive healthcare platform.
Industries
Nr. of Employees
small (1-50)
Algernon Pharmaceuticals
601 West Broadway, Suite 400, Vancouver, BC V5Z 4C2, Canada
Patents
Use of repirinast in the prophylaxis or treatment of renal fibrosis or kidney disease
US-12280026-B2
View Details
Use of repirinast in the prophylaxis or treatment of renal fibrosis or kidney disease
US-12280026-B2
View DetailsProducts
Repirinast (NP-251) — repurposing candidate for kidney fibrosis
A previously marketed small molecule being advanced as a repurposed therapy for chronic kidney disease based on preclinical fibrosis reduction data.
DMT program (AP-188) for stroke and traumatic brain injury
Research and clinical development program investigating N,N‑Dimethyltryptamine (DMT) as a potential treatment to induce neuroplasticity and support recovery after ischemic stroke and traumatic brain injury.
Ifenprodil program (formerly NP-120) — asset divestiture
Previously advanced program for respiratory and fibrotic pulmonary indications that was transferred/sold to an external drug development company.
Repirinast (NP-251) — repurposing candidate for kidney fibrosis
A previously marketed small molecule being advanced as a repurposed therapy for chronic kidney disease based on preclinical fibrosis reduction data.
DMT program (AP-188) for stroke and traumatic brain injury
Research and clinical development program investigating N,N‑Dimethyltryptamine (DMT) as a potential treatment to induce neuroplasticity and support recovery after ischemic stroke and traumatic brain injury.
Ifenprodil program (formerly NP-120) — asset divestiture
Previously advanced program for respiratory and fibrotic pulmonary indications that was transferred/sold to an external drug development company.
Services
Design and conduct of Phase 1 and Phase 2 clinical studies for repurposed small molecules and naturally occurring compounds, including site selection and regulatory submissions.
Comprehensive clinic services including cognitive and genetic screening, blood biomarker testing, brain‑specific PET imaging, and infusion administration of approved antibody therapies.
Provision of dedicated brain PET imaging services and scanning capacity to support external drug development studies requiring amyloid or other molecular imaging endpoints.
Management and fundraising for a private subsidiary focused on advancing a naturally occurring compound program through Phase 1 and Phase 2a clinical studies using Reg A+ and other capital markets mechanisms.
Design and conduct of Phase 1 and Phase 2 clinical studies for repurposed small molecules and naturally occurring compounds, including site selection and regulatory submissions.
Comprehensive clinic services including cognitive and genetic screening, blood biomarker testing, brain‑specific PET imaging, and infusion administration of approved antibody therapies.
Provision of dedicated brain PET imaging services and scanning capacity to support external drug development studies requiring amyloid or other molecular imaging endpoints.
Management and fundraising for a private subsidiary focused on advancing a naturally occurring compound program through Phase 1 and Phase 2a clinical studies using Reg A+ and other capital markets mechanisms.
Expertise Areas
- Drug repurposing and repositioning
- Early‑phase clinical development (Phase 1/2)
- Neurology and neurorehabilitation research (stroke, TBI, Alzheimer’s)
- Preclinical pharmacology and animal models
Key Technologies
- Ultra‑compact brain PET imaging
- Radiotracer‑based amyloid PET imaging
- Blood‑based phosphorylated tau assays
- Genetic testing for APOE status
News & Updates
The company announced a private placement of $1 million to fund research and development activities.
The acquisition aims to establish Alzheimer’s diagnostic and treatment clinics featuring new PET scan technology.
Plans to open clinics in North America with advanced PET scan technology and FDA-approved therapies.
The company announced a private placement of $1 million to fund research and development activities.
The acquisition aims to establish Alzheimer’s diagnostic and treatment clinics featuring new PET scan technology.
Plans to open clinics in North America with advanced PET scan technology and FDA-approved therapies.